0RK9 Stock Chart & Stats
kr0.05
kr0.00(0.00%)
At close: 4:00 PM EDT
kr0.05
kr0.00(0.00%)
Day’s Range― - ―
52-Week Rangekr0.03 - kr1.52
Previous CloseN/A
Volume0.00
Average Volume (3M)6.90K
Market Cap
kr16.20M
Enterprise Valuekr93.66
Total Cash (Recent Filing)kr32.98M
Total Debt (Recent Filing)kr32.38M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding534,516,970
10 Day Avg. Volume9,644
30 Day Avg. Volume6,900
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.35
Price to Sales (P/S)18.04
P/FCF Ratio-0.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.75
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Oncology PipelineA focused oncology pipeline gives Alligator exposure to a large unmet medical need. Successful clinical progress could create licensing or milestone opportunities, although value depends on development and regulatory execution.
Improved Balance SheetLower leverage and positive equity provide more financial flexibility than in prior periods. This may help the company fund development activities or negotiate partnerships from a stronger capital position.
Reduced Cash BurnImprovement in cash burn indicates some progress in controlling funding requirements. If sustained, it could extend the development runway and reduce the frequency or urgency of external capital raising.
Bears Say
Sharp Revenue DeclineMinimal and declining revenue shows that the business has not established dependable commercial or partnership income. This leaves results highly exposed to the timing of deals, milestones and development progress.
Persistent UnprofitabilityRepeated operating and net losses indicate the model has not yet scaled to sustainable profitability. Continued losses could erode equity and increase dependence on financing or strategic transactions.
Ongoing Funding NeedDeeply negative cash generation means ongoing research and operating costs are not self-funded. Unless cash use improves materially or partnerships provide funding, additional capital may be required to advance the pipeline.
Alligator Bioscience AB News
0RK9 FAQ
What was Alligator Bioscience AB’s price range in the past 12 months?
Alligator Bioscience AB lowest share price was kr0.03 and its highest was kr1.52 in the past 12 months.
What is Alligator Bioscience AB’s market cap?
Alligator Bioscience AB’s market cap is kr16.20M.
When is Alligator Bioscience AB’s upcoming earnings report date?
Alligator Bioscience AB’s upcoming earnings report date is Aug 26, 2026 which is in 3 days.
How were Alligator Bioscience AB’s earnings last quarter?
Alligator Bioscience AB released its earnings results on May 05, 2026. The company reported kr0.003 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Alligator Bioscience AB overvalued?
According to Wall Street analysts Alligator Bioscience AB’s price is currently Overvalued.
Does Alligator Bioscience AB pay dividends?
Alligator Bioscience AB does not currently pay dividends.
What is Alligator Bioscience AB’s EPS estimate?
Alligator Bioscience AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alligator Bioscience AB have?
Alligator Bioscience AB has 534,516,970 shares outstanding.
What happened to Alligator Bioscience AB’s price movement after its last earnings report?
Alligator Bioscience AB reported an EPS of kr0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.408%.
Which hedge fund is a major shareholder of Alligator Bioscience AB?
Currently, no hedge funds are holding shares in GB:0RK9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alligator Bioscience AB
Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its drug development. These include ALLIGATOR-GOLD and ALLIGATOR-FAB, an extensive human antibody library boasting roughly 60 billion distinct antibody fragments; FIND, a molecular evolution technique used for optimizing antibodies and other proteins; and RUBY, a specialized format for creating bispecific antibodies. Alligator Bioscience's pipeline features several promising candidates. In the clinical stage, Mitazalimab, an immunostimulatory CD40 antibody, has successfully completed Phase I trials for metastatic cancer. Also undergoing Phase I clinical evaluation is ATOR-1017, another immunostimulatory antibody designed to bind to the 4-1BB receptor on tumor-specific T cells. For its preclinical efforts, the company is advancing ALG.APV-527, a bispecific antibody targeting both 4-1BB and 5T4 for cancer therapy. Additionally, Alligator Bioscience holds an interest in the Biosynergy (AC101) project, which is currently in Phase I. To bolster its research and development capabilities, Alligator Bioscience has formed multiple strategic collaborations. It has a co-development partnership with Aptevo Therapeutics Inc. for ALG.APV-527, and a research alliance with MacroGenics, Inc. to create novel immunotherapies. Further collaborations include a joint research agreement with BioArctic AB (publ) to utilize proprietary antibody generation technologies for new product candidates, and a research and license agreement with Orion Corporation aimed at discovering and developing new bispecific antibody cancer therapeutics. The company was established in 2000.
Technical Analysis
BioInvent International AB
―
Oncopeptides AB
―
Elicera Therapeutics AB
―
Immunicum AB
―
Cantargia AB
―